L3VLUP
ProSign in

NBIX · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NBIXAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NBIX
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterNBIXAMGN
Q3 202015 holders, $2.6bn16 holders, $16.3bn
Q4 202012 holders, $2.6bn19 holders, $14.0bn
Q1 20216 holders, $2.3bn16 holders, $14.5bn
Q2 20219 holders, $1.5bn23 holders, $13.8bn
Q3 20218 holders, $1.5bn24 holders, $11.6bn
Q4 202114 holders, $1.3bn21 holders, $10.4bn
Q1 202215 holders, $1.4bn23 holders, $9.9bn
Q2 202211 holders, $1.3bn28 holders, $9.7bn
Q3 202214 holders, $1.0bn21 holders, $7.9bn
Q4 202215 holders, $1.2bn24 holders, $9.3bn
Q1 202317 holders, $860m22 holders, $8.4bn
Q2 202316 holders, $1.1bn26 holders, $7.4bn
Q3 202324 holders, $1.4bn26 holders, $8.7bn
Q4 202321 holders, $1.6bn24 holders, $8.4bn
Q1 202419 holders, $1.5bn25 holders, $6.7bn
Q2 202417 holders, $1.4bn20 holders, $8.0bn
Q3 202411 holders, $1.2bn21 holders, $8.8bn
Q4 202414 holders, $2.0bn20 holders, $8.2bn
Q1 202514 holders, $1.6bn25 holders, $12.0bn
Q2 202516 holders, $2.5bn20 holders, $10.2bn
Q3 202515 holders, $2.6bn17 holders, $10.4bn
Q4 202521 holders, $2.8bn19 holders, $18.0bn
Q1 202617 holders, $2.9bn15 holders, $21.4bn
Q2 202610 holders, $2.7bn23 holders, $24.9bn
NBIX

Neurocrine Biosciences Inc

Holders
11
Reported value
$1.2bn
Buyers
7
Sellers
5

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
21
Reported value
$8.8bn
Buyers
16
Sellers
5

Breadth +11 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2024

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NBIX (6)

Bridgewater Associates LP, Citadel Advisors LLC, Hudson Bay Capital Management LP, PDT Partners LLC, Renaissance Technologies LLC, Soros Fund Management LLC

Only AMGN (16)

AllianceBernstein LP, ARK Investment Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Fidelity (FMR LLC), Invesco Ltd, Marshall Wace LLP, Neuberger Berman Group LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →